Baidu
map

Cancer Cell:还在质疑高剂量维C抗癌?人体安全试验已通过

2017-04-02 佚名 转化医学网

临床试验发现,定期给脑癌和肺癌患者注射800-1000倍日常服用量的维生素C作为改进常规癌症治疗效果的策略是安全的。在2017年3月30日提交的癌细胞研究工作报告中,爱荷华大学的研究人员展示了一令人惊讶的研究成果:改变癌细胞的铁代谢途径,导致癌细胞对高剂量维生素C引起的死亡敏感性增加。


临床试验发现,定期给脑癌和肺癌患者注射800-1000倍日常服用量的维生素C作为改进常规癌症治疗效果的策略是安全的。在2017年3月30日提交的癌细胞研究工作报告中,爱荷华大学的研究人员展示了一令人惊讶的研究成果:改变癌细胞的铁代谢途径,导致癌细胞对高剂量维生素C引起的死亡敏感性增加。

首次提出癌细胞易受氧化还原活性复合物影响假说的作者Garry Buettner说:“这篇文章揭示了癌细胞代谢的脆弱性,使我们能够利用现有的氧化还原活性化合物,如维生素C,使癌细胞对辐射和化疗变得更加敏感。”Buettner以及资深作家Bryan Allen和Douglas Spitz是爱荷华大学辐射肿瘤学系的教员。

在这项研究中,参加安全性试验的11名脑癌患者每周接受三次维生素C注射,注射持续2个月,随后每周接受两次维生素C注射,持续7个月,同时接受常规辐射和化疗治疗。与大多数成年人血液内70μM的维生素C含量相比,研究人员每次向患者体内注入维生素C的浓度高达20,000μM。 研究人员指出,高剂量的维生素C是必需的,因为维生素C在体内的循环仅有两个小时的半衰期。 维生素C治疗伴有轻微的副作用,如口干。

为什么这种方法安全?因为即使高剂量,维生素C对正常细胞也无毒性。同时爱荷华大学的研究小组发现,肿瘤组织内高水平的氧化还原活性铁分子(线粒体代谢异常的副产物)与维生素C反应形成过氧化氢和过氧化氢自由基。 这些自由基可以在癌细胞(相对于正常细胞)中选择性损伤DNA,导致癌细胞死亡以及癌细胞对辐射和化疗的敏感性增加。

生物化学研究学者Douglas Spit表示:“这是一个重要的例子,表明癌症以及正常细胞中氧化还原活性复合物的基础科学研究在临床上可用于癌症治疗。这项研究提出了令人信服的证据证实,癌细胞中增加的氧化还原活性金属离子是导致癌细胞对高剂量维生素C敏感的根本原因。”

研究为进一步确定高剂量维生素C是否有效延长患者接受放疗和化疗的总体寿命和生活质量,设置了II期临床试验。目前,研究人员正在招募肺癌患者,并将在II期试验中继续招募多形性胶质母细胞瘤(脑癌)患者。他们希望在II期试验中可以增强脑癌患者对放疗和化疗的反应。 这种保守的乐观是基于I期试验数据,I期试验数据显示11名脑癌患者(18-22个月)的总生存期增加4-6个月,而标准治疗通常仅有14-16个月的存活时间。

研究领导者Bryan Allen说:“我们合作的大多数癌症患者都很乐意参与临床试验,临床试验结果看起来很有希望,但我们不知道这种方法是否真的改善了治疗反应,直到我们完成II期试验。”

每个患者在II期试验中维生素C注射的费用约为8000美元。这种成本低于一些免疫治疗或化疗药物治疗。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2174667, encodeId=8ad121e466736, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de549106593, createdName=ms6000002079940939, createdTime=Wed Dec 13 10:16:37 CST 2023, time=2023-12-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1960103, encodeId=84b31960103f2, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Feb 17 12:25:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735098, encodeId=a3441e350985d, content=<a href='/topic/show?id=9aa5923e176' target=_blank style='color:#2F92EE;'>#质疑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92371, encryptionId=9aa5923e176, topicName=质疑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d3033872914, createdName=saikp, createdTime=Sun Jul 16 19:25:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869844, encodeId=deb11869844b1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Oct 27 19:25:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942059, encodeId=5675194205907, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sat Sep 09 21:25:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822226, encodeId=6e191822226d0, content=<a href='/topic/show?id=e39010223eef' target=_blank style='color:#2F92EE;'>#高剂量维C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102237, encryptionId=e39010223eef, topicName=高剂量维C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat Dec 30 09:25:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780712, encodeId=649f1e80712a8, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Apr 22 03:25:00 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184906, encodeId=d25d18490686, content=学习了,多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Mon Apr 03 16:51:08 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
    2023-12-13 ms6000002079940939 来自广东省

    感谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2174667, encodeId=8ad121e466736, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de549106593, createdName=ms6000002079940939, createdTime=Wed Dec 13 10:16:37 CST 2023, time=2023-12-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1960103, encodeId=84b31960103f2, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Feb 17 12:25:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735098, encodeId=a3441e350985d, content=<a href='/topic/show?id=9aa5923e176' target=_blank style='color:#2F92EE;'>#质疑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92371, encryptionId=9aa5923e176, topicName=质疑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d3033872914, createdName=saikp, createdTime=Sun Jul 16 19:25:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869844, encodeId=deb11869844b1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Oct 27 19:25:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942059, encodeId=5675194205907, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sat Sep 09 21:25:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822226, encodeId=6e191822226d0, content=<a href='/topic/show?id=e39010223eef' target=_blank style='color:#2F92EE;'>#高剂量维C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102237, encryptionId=e39010223eef, topicName=高剂量维C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat Dec 30 09:25:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780712, encodeId=649f1e80712a8, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Apr 22 03:25:00 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184906, encodeId=d25d18490686, content=学习了,多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Mon Apr 03 16:51:08 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
    2018-02-17 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=2174667, encodeId=8ad121e466736, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de549106593, createdName=ms6000002079940939, createdTime=Wed Dec 13 10:16:37 CST 2023, time=2023-12-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1960103, encodeId=84b31960103f2, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Feb 17 12:25:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735098, encodeId=a3441e350985d, content=<a href='/topic/show?id=9aa5923e176' target=_blank style='color:#2F92EE;'>#质疑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92371, encryptionId=9aa5923e176, topicName=质疑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d3033872914, createdName=saikp, createdTime=Sun Jul 16 19:25:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869844, encodeId=deb11869844b1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Oct 27 19:25:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942059, encodeId=5675194205907, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sat Sep 09 21:25:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822226, encodeId=6e191822226d0, content=<a href='/topic/show?id=e39010223eef' target=_blank style='color:#2F92EE;'>#高剂量维C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102237, encryptionId=e39010223eef, topicName=高剂量维C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat Dec 30 09:25:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780712, encodeId=649f1e80712a8, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Apr 22 03:25:00 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184906, encodeId=d25d18490686, content=学习了,多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Mon Apr 03 16:51:08 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
    2017-07-16 saikp
  4. [GetPortalCommentsPageByObjectIdResponse(id=2174667, encodeId=8ad121e466736, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de549106593, createdName=ms6000002079940939, createdTime=Wed Dec 13 10:16:37 CST 2023, time=2023-12-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1960103, encodeId=84b31960103f2, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Feb 17 12:25:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735098, encodeId=a3441e350985d, content=<a href='/topic/show?id=9aa5923e176' target=_blank style='color:#2F92EE;'>#质疑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92371, encryptionId=9aa5923e176, topicName=质疑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d3033872914, createdName=saikp, createdTime=Sun Jul 16 19:25:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869844, encodeId=deb11869844b1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Oct 27 19:25:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942059, encodeId=5675194205907, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sat Sep 09 21:25:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822226, encodeId=6e191822226d0, content=<a href='/topic/show?id=e39010223eef' target=_blank style='color:#2F92EE;'>#高剂量维C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102237, encryptionId=e39010223eef, topicName=高剂量维C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat Dec 30 09:25:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780712, encodeId=649f1e80712a8, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Apr 22 03:25:00 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184906, encodeId=d25d18490686, content=学习了,多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Mon Apr 03 16:51:08 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2174667, encodeId=8ad121e466736, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de549106593, createdName=ms6000002079940939, createdTime=Wed Dec 13 10:16:37 CST 2023, time=2023-12-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1960103, encodeId=84b31960103f2, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Feb 17 12:25:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735098, encodeId=a3441e350985d, content=<a href='/topic/show?id=9aa5923e176' target=_blank style='color:#2F92EE;'>#质疑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92371, encryptionId=9aa5923e176, topicName=质疑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d3033872914, createdName=saikp, createdTime=Sun Jul 16 19:25:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869844, encodeId=deb11869844b1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Oct 27 19:25:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942059, encodeId=5675194205907, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sat Sep 09 21:25:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822226, encodeId=6e191822226d0, content=<a href='/topic/show?id=e39010223eef' target=_blank style='color:#2F92EE;'>#高剂量维C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102237, encryptionId=e39010223eef, topicName=高剂量维C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat Dec 30 09:25:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780712, encodeId=649f1e80712a8, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Apr 22 03:25:00 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184906, encodeId=d25d18490686, content=学习了,多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Mon Apr 03 16:51:08 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
    2017-09-09 amy0550
  6. [GetPortalCommentsPageByObjectIdResponse(id=2174667, encodeId=8ad121e466736, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de549106593, createdName=ms6000002079940939, createdTime=Wed Dec 13 10:16:37 CST 2023, time=2023-12-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1960103, encodeId=84b31960103f2, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Feb 17 12:25:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735098, encodeId=a3441e350985d, content=<a href='/topic/show?id=9aa5923e176' target=_blank style='color:#2F92EE;'>#质疑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92371, encryptionId=9aa5923e176, topicName=质疑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d3033872914, createdName=saikp, createdTime=Sun Jul 16 19:25:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869844, encodeId=deb11869844b1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Oct 27 19:25:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942059, encodeId=5675194205907, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sat Sep 09 21:25:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822226, encodeId=6e191822226d0, content=<a href='/topic/show?id=e39010223eef' target=_blank style='color:#2F92EE;'>#高剂量维C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102237, encryptionId=e39010223eef, topicName=高剂量维C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat Dec 30 09:25:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780712, encodeId=649f1e80712a8, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Apr 22 03:25:00 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184906, encodeId=d25d18490686, content=学习了,多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Mon Apr 03 16:51:08 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2174667, encodeId=8ad121e466736, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de549106593, createdName=ms6000002079940939, createdTime=Wed Dec 13 10:16:37 CST 2023, time=2023-12-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1960103, encodeId=84b31960103f2, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Feb 17 12:25:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735098, encodeId=a3441e350985d, content=<a href='/topic/show?id=9aa5923e176' target=_blank style='color:#2F92EE;'>#质疑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92371, encryptionId=9aa5923e176, topicName=质疑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d3033872914, createdName=saikp, createdTime=Sun Jul 16 19:25:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869844, encodeId=deb11869844b1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Oct 27 19:25:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942059, encodeId=5675194205907, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sat Sep 09 21:25:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822226, encodeId=6e191822226d0, content=<a href='/topic/show?id=e39010223eef' target=_blank style='color:#2F92EE;'>#高剂量维C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102237, encryptionId=e39010223eef, topicName=高剂量维C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat Dec 30 09:25:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780712, encodeId=649f1e80712a8, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Apr 22 03:25:00 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184906, encodeId=d25d18490686, content=学习了,多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Mon Apr 03 16:51:08 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2174667, encodeId=8ad121e466736, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de549106593, createdName=ms6000002079940939, createdTime=Wed Dec 13 10:16:37 CST 2023, time=2023-12-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1960103, encodeId=84b31960103f2, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Feb 17 12:25:00 CST 2018, time=2018-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735098, encodeId=a3441e350985d, content=<a href='/topic/show?id=9aa5923e176' target=_blank style='color:#2F92EE;'>#质疑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92371, encryptionId=9aa5923e176, topicName=质疑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d3033872914, createdName=saikp, createdTime=Sun Jul 16 19:25:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869844, encodeId=deb11869844b1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Oct 27 19:25:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942059, encodeId=5675194205907, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sat Sep 09 21:25:00 CST 2017, time=2017-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822226, encodeId=6e191822226d0, content=<a href='/topic/show?id=e39010223eef' target=_blank style='color:#2F92EE;'>#高剂量维C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102237, encryptionId=e39010223eef, topicName=高剂量维C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat Dec 30 09:25:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780712, encodeId=649f1e80712a8, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Apr 22 03:25:00 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184906, encodeId=d25d18490686, content=学习了,多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOWcPEsEP4FrvDcicue5V6rMkmXmY73KjYP59vQrEdjU89iaN4ZkOhsItlHkmGTjhV3b5S3zOQA4E0/0, createdBy=cc261682151, createdName=卡圣, createdTime=Mon Apr 03 16:51:08 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
    2017-04-03 卡圣

    学习了,多谢分享

    0

相关资讯

盘点维生素C功能研究新近进展

维生素C(Vc,又称L-抗坏血酸)是高等灵长类动物与其他少数生物的必需营养素。抗坏血酸在大多的生物体可借由新陈代谢制造出来,但是人类是最显著的例外。最广为人知的是缺乏维生素C会造成坏血病。在生物体内,维生素C是一种抗氧化剂,保护身体免于自由基的威胁,维生素C同时也是一种辅酶。其广泛的食物来源为各类新鲜蔬果。 不过,人类不能自己制造人体必需的维生素C。这是因为人类本来用于制造维生素C的

显微镜下的科学炫美图,它们的真实身份是?

日前,尼康公司宣布了第42届尼康Small World显微摄影大赛的结果。尼康Small Word是一个著名的通过光学显微镜下看到的图片来展现生命的复杂性和美丽的论坛。任何对显微镜和照相感兴趣的人都可以递交照片参与显微摄影大赛。这次大赛收集了世界各地70个国家的科学家、摄影师和业余爱好者的2000多幅作品。评审们根据作品的艺术性和科学技术性选出获奖作品。▲ 四天大的斑马鱼胚胎的“自拍照”本次大赛的

Chest:氢化可的松、维生素C、维生素B1对脓毒症的疗效评估

这些研究结果表明,早期静脉注射维生素C以及加上糖皮质激素和维生素B1,可能被证明是有效的预防包括急性肾损伤在内的进行性器官功能障碍,降低严重脓毒症和感染性休克患者的死亡率。但需要更多的研究来证实这些初步的发现。

BMJ:至今仍盛行的一种历史性疾病-案例报道

维生素C水平进行了检查,由于高度的临床怀疑开始口服抗坏血酸(100mg,三次日常)。接下来证实维生素C水平<5μmol/L(正常范围为15-90 μmol/L)。病人由营养师进行了评估,出院后伴随社区营养师随访计划。四周后患者疲劳和皮肤改变消失。6周后复查全血液计数,血红蛋白水平正常。

Oncotarget:维生素C抗癌活力竟是肿瘤药物的十倍!

在一项最新发表国际知名肿瘤学杂志Oncotarget上的文章中,研究人员介绍了三种天然物质,三种实验药物以及一种在临床上用于抑制肿瘤干细胞(CSCs)生长的特效药。

Sci Signal:维生素C的新功能-预防小胶质细胞激活

总体而言,该研究的结果表明抗坏血酸转运系统对于维持小胶质细胞动态平衡的重要性,以及提示抗坏血酸转运失调可能参与了神经系统疾病的发生发展。

Baidu
map
Baidu
map
Baidu
map